SRTA

#2886
Strata Critical Medical, Inc. - Class A Common Stock
5.9 7 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.97
5.97
Intervallo Annuale
3.85
6.50
Variazione giornaliera
-3.24%
Variazione Mensile
+18.22%
Variazione di 6 mesi
+42.14%
Variazione Annuale
+38.19%
Chiusura Precedente
6.1 7
Open
5.9 7
Minimo
5.9 7
Massimo
5.9 7
Volume
62
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Strata Critical Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Strata Critical Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Strata Critical Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Strata Critical Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K

Strata Critical Medical, Inc. current report, Q2 FY2026

Full document

Strata Critical Medical, Inc. (SRTA) - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 28, 2026, details the results of the Annual Meeting of Stockholders held by Strata Critical Medical, Inc. on that date. The filing covers the election of directors, ratification of the independent auditor, and the advisory vote on executive compensation.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

The following proposals were submitted to a vote of security holders with the following outcomes:

  • Election of Class II Directors: Stockholders elected two directors to serve until the 2029 annual meeting.
    • William A. Heyburn: 46,050,902 votes For; 505,421 votes Withhold; 12,687,496 Broker Non-Votes.
    • Andrew Lauck: 39,525,159 votes For; 7,031,164 votes Withhold; 12,687,496 Broker Non-Votes.
  • Ratification of Independent Auditor: Stockholders ratified the appointment of Deloitte & Touche LLP for the fiscal year ending December 31, 2026.
    • Results: 58,946,832 votes For; 65,815 votes Against; 231,172 votes Abstain.
  • Advisory Say-on-Pay Vote: Stockholders approved the compensation of named executive officers on a non-binding basis.
    • Results: 38,497,962 votes For; 8,022,682 votes Against; 35,679 votes Abstain; 12,687,496 Broker Non-Votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The report is limited to the disclosure of voting results.

Key Facts for Investor Verification

  • Verify the definitive proxy statement filed on April 14, 2026, for detailed background on the director nominees and executive compensation.
  • Note the significant number of Broker Non-Votes (12,687,496) recorded for the director election and Say-on-Pay proposals.
  • Confirm the tenure of the newly elected directors, which extends until the 2029 annual meeting.
  • Review the upcoming fiscal year-end of December 31, 2026, for which Deloitte & Touche LLP has been ratified as the auditor.